BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 1931570)

  • 1. Autoantibodies in scleroderma and polymyositis: an update.
    McCarty GA
    Semin Dermatol; 1991 Sep; 10(3):206-16. PubMed ID: 1931570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Spectrum of antinuclear and anti-cytoplasmic antibodies in dermatomyositis and polymyositis overlap syndromes].
    Meurer M; Hausmann-Martinez-Pardo G; Braun-Falco O
    Hautarzt; 1989 Oct; 40(10):623-9. PubMed ID: 2482267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cellular immunity and the autoantibody system in polymyositis and dermatomyositis].
    Ljubicić N; Cikes N
    Lijec Vjesn; 1991; 113(3-4):95-9. PubMed ID: 1890925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Occurrence of autoantibodies and the clinical course of mixed connective tissue disease, systemic scleroderma, dermatomyositis, polymyositis and Sjögren's syndrome].
    Prokop J; Zietkiewicz E; Słomski R
    Przegl Dermatol; 1986; 73(4):327-31. PubMed ID: 3333867
    [No Abstract]   [Full Text] [Related]  

  • 5. [Polymyositis/scleroderma autoantibody-positive scleroderma with dermatomyositis (scleromyositis)].
    Török L; Dankó K; Cserni G; Szücs G
    Orv Hetil; 2002 Nov; 143(45):2553-6. PubMed ID: 12501562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
    Schilders G; Egberts WV; Raijmakers R; Pruijn GJ
    Arthritis Rheum; 2007 Jul; 56(7):2449-54. PubMed ID: 17599775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy.
    Kao AH; Lacomis D; Lucas M; Fertig N; Oddis CV
    Arthritis Rheum; 2004 Jan; 50(1):209-15. PubMed ID: 14730618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights.
    Mahler M; Raijmakers R
    Autoimmun Rev; 2007 Aug; 6(7):432-7. PubMed ID: 17643929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies.
    Dugan EM; Huber AM; Miller FW; Rider LG;
    Dermatol Online J; 2009 Feb; 15(2):2. PubMed ID: 19336019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Autoantibodies in collagen diseases].
    Meyer O
    Ann Med Interne (Paris); 1986; 137(8):666-78. PubMed ID: 2436515
    [No Abstract]   [Full Text] [Related]  

  • 11. Marker antibodies in scleroderma and polymyositis: clinical associations.
    de Rooij DJ; Van de Putte LB; Habets WJ; Van Venrooij WJ
    Clin Rheumatol; 1989 Jun; 8(2):231-7. PubMed ID: 2547546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel autoantibodies in inflammatory myopathies and systemic sclerosis].
    Ribi C
    Rev Med Suisse; 2015 Jan; 11(456-457):25-9. PubMed ID: 25799647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Laboratory diagnostics of polymyositis/dermatomyositis].
    Prus V; Bedeković D
    Reumatizam; 2012; 59(2):27-30. PubMed ID: 23745451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells.
    Arahata K; Engel AG
    Ann Neurol; 1984 Aug; 16(2):193-208. PubMed ID: 6383191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease.
    Shah AA; Rosen A; Hummers LK; May BJ; Kaushiva A; Roden RBS; Armstrong DK; Wigley FM; Casciola-Rosen L; Visvanathan K
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):71-74. PubMed ID: 28628466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of autoimmune diseases: recent trends--with special reference to progress in immunological tests and therapeutic methods. Systemic autoimmune diseases. 2) Systemic scleroderma and polymyositis].
    Kinoshita M; Yokohari R
    Nihon Rinsho; 1988 Apr; 46(4):873-8. PubMed ID: 3261361
    [No Abstract]   [Full Text] [Related]  

  • 17. [Diagnostic significance of scleroderma and myositis-associated autoantibodies].
    Genth E; Mierau R
    Z Rheumatol; 1995; 54(1):39-49. PubMed ID: 7725809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies and their relation to rheumatic diseases.
    McCarty GA
    Med Clin North Am; 1986 Mar; 70(2):237-61. PubMed ID: 2419715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoserological aspects of idiopathic inflammatory muscle disease.
    Rozman B; Bozic B; Kos-Golja M; Plesivcnik-Novljan M; Kveder T
    Wien Klin Wochenschr; 2000 Aug; 112(15-16):722-7. PubMed ID: 11020964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibody testing for autoimmune disease.
    Self SE
    Clin Chest Med; 2010 Sep; 31(3):415-22. PubMed ID: 20692536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.